# A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

> **NCT04035486** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 587 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Pemetrexed/Carboplatin
- **DRUG:** Pemetrexed/Cisplatin

## Key facts

- **NCT ID:** NCT04035486
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-02
- **Primary completion:** 2023-04-03
- **Final completion:** 2026-12-22
- **Target enrollment:** 587 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04035486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04035486, "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04035486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*